ndv-01
Generic: gemcitabine and docetaxel
ndv-01: developed by 1 company · 1 clinical trial tracked · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | Phase 3 |
Clinical Trials (1)
A Phase 3 Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy
FDA Decisions
FDA_MeetingCompany will request Type B meetings for the randomized intermediate-risk NMIBC trial and the BCG-unresponsive trial following recent FDA feedback.(RLMD)
Frequently asked questions
Who is developing ndv-01?
ndv-01 is being developed by RELMADA THERAPEUTICS, INC..
How many clinical trials involve ndv-01?
BioSniper tracks 1 clinical trial involving ndv-01.
What is ndv-01's latest FDA decision?
The most recent tracked FDA decision for ndv-01 is FDA_Meeting for Company will request Type B meetings for the randomized intermediate-risk NMIBC trial and the BCG-unresponsive trial following recent FDA feedback..
Get deeper analysis on ndv-01
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis